Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
Target enrollment of 6,000 participants completed in the Northern Hemisphere Planned interim analysis in Q1 2026 will determine potential need...